Adagene Announces FDA Clearance To Proceed With Phase 1b/2 Trial Of Anti-CTLA-4 ADG126 Safebody® In Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
– ADG126-P001 trial being initiated at multiple sites in U.S. and Asia Pacific – – First SAFEbody candidate to advance into combination clinical trial, building on strong single-agent clinical profile – SAN DIEGO and SUZHOU, China, March 17 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development…

